



Rexahn Pharmaceuticals, Inc.  
Investor Relations Department  
15245 Shady Grove Road, Suite  
455  
Rockville, MD 20850  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

AMEX: RNN

Last Trade:	1.80
Trade Time:	12:50 PM ET 08/22/17
Change:	-0.03 <span style="color: red;">↓</span> (1.623%)
Day Range	1.80 - 1.87
52-Week Range	1.27 - 7.10
Volume	38,122

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- 08/14/17**  
[Rexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans](#)
- 08/07/17**  
[Rexahn Pharmaceuticals Reports Second Quarter 2017 Financial and Operational Results](#)
- 07/10/17**  
[Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117](#)
- 06/07/17**  
[Rexahn Announces \\$10 Million Registered Direct Offering](#)
- 06/04/17**  
[Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology \(ASCO\) 2017 Annual Meeting](#)

## Financials [\[ View all \]](#)

- [Fourth Quarter Financial Results](#)
- 02/24/17**  
[Annual Report \(10-K\)](#)
- 02/24/17**  
[Proxy Statement \(DEF 14A\)](#)
- 08/04/17**  
[Quarterly Report \(10-Q\)](#)
- 05/03/17**  
[Quarterly Report \(10-Q\)](#)
- 11/04/16**  
[Quarterly Report \(10-Q\)](#)